zinc finger protein 849, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ZNF849P profile across patient tissues and cancer cell-line models. ZNF849P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ZNF849P is differentially expressed in 8, with the highest sampling consensus in UCEC. Additionally, ZNF849P RNA expression shows 14,427 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight PAAD, UCEC, and THYM as cancer lineages where ZNF849P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF849P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF849P survival associations across molecular data types. ZNF849P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF849P RNA expression–survival associations across cancer types. High ZNF849P expression shows unfavorable associations in PAAD, UCEC, LUSC and ACC, but favorable associations in LGG and UCS. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify PAAD as the clearest survival context for ZNF849P RNA expression.
This table summarizes ZNF849P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF849P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF849P shows lower tumor expression in COAD and LUSC and higher tumor expression in UCEC, KIRP, BRCA and LIHC. The UCEC box plot shows higher ZNF849P RNA expression in tumor versus normal tissue (log2 FC = +0.367, t-test p = .001).
This table shows molecular features associated with ZNF849P in patient tissues and cancer cell lines. In patient samples, ZNF849P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
